East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lidocaine Ointment USP, 5%. Aurobindo Pharma’s Lidocaine Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Lidocaine Ointment manufactured by Fougera Pharmaceuticals Inc.

Lidocaine Ointment are indicated:

• For production of anesthesia of accessible mucous membranes of the oropharynx
• As an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites.